Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LINE-AD: Emtriva in Alzheimer's Disease
NCT04500847Phase 1Recruiting
- Sponsor
- Butler Hospital
- Start
- Dec 2021
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing Emtriva with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Dec 2021; status: recruiting.
02
Drugs
emtricitabine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04500847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04500847.